Reasons to Avoid Investing in Revvity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Yahoo Finance
- Organic Growth Weakness: Revvity's organic revenue growth averaged only 2.9% annually over the past two years, lagging behind the sector, indicating waning demand in its core business and the need for product and market strategy improvements to remain competitive.
- Declining Adjusted Operating Margin: The company's adjusted operating margin has decreased by 6 percentage points over the last five years, currently standing at 27%, which raises concerns among shareholders about future profitability improvements to enhance investment appeal.
- Falling EPS: Revvity's earnings per share (EPS) has declined by 14.7% annually over the past five years, suggesting that while revenue may have increased, the company's fixed cost structure has hindered its ability to adapt to decreasing demand, negatively impacting profitability.
- Overpriced Market Valuation: With a forward P/E ratio of 20.3 and a stock price of $112.79, Revvity's shares appear to be priced for significant positive expectations, leading analysts to recommend that investors consider other stocks with better potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 112.840
Low
105.00
Averages
113.38
High
123.00
Current: 112.840
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reasons to Avoid Investing in Revvity
- Organic Growth Weakness: Revvity's organic revenue growth averaged only 2.9% annually over the past two years, lagging behind the sector, indicating waning demand in its core business and the need for product and market strategy improvements to remain competitive.
- Declining Adjusted Operating Margin: The company's adjusted operating margin has decreased by 6 percentage points over the last five years, currently standing at 27%, which raises concerns among shareholders about future profitability improvements to enhance investment appeal.
- Falling EPS: Revvity's earnings per share (EPS) has declined by 14.7% annually over the past five years, suggesting that while revenue may have increased, the company's fixed cost structure has hindered its ability to adapt to decreasing demand, negatively impacting profitability.
- Overpriced Market Valuation: With a forward P/E ratio of 20.3 and a stock price of $112.79, Revvity's shares appear to be priced for significant positive expectations, leading analysts to recommend that investors consider other stocks with better potential.
See More
Market Capitalization Comparison: Revvity vs Clorox
- Market Cap Comparison: Revvity Inc (Ticker: RVTY) has a market capitalization of $11.78 billion compared to Clorox Co (Ticker: CLX) at $11.53 billion, indicating Revvity's relative strength in the market, which may attract more investor interest.
- Investor Misconceptions: Many novice investors mistakenly compare company values solely based on stock prices; however, market capitalization provides a more accurate assessment of a company's value, aiding investors in making informed decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to hold the stock, particularly as large funds tend to focus on companies valued over $10 billion.
- Stock Performance: At Thursday's close, Revvity's stock rose approximately 7.6%, while Clorox fell about 0.2%, reflecting positive market sentiment and increased investor confidence in Revvity.
See More
U.S. Stocks Close Higher, Led by Tech Gains
- Tech Stock Surge: Intel's stock soared over 12% after Apple held exploratory talks with Intel and Samsung Electronics for U.S. processor production, indicating strong market confidence in tech stocks and driving gains across chipmakers.
- Oil Price Decline: WTI crude oil prices fell more than 3% as the ceasefire in the Middle East eased geopolitical risks, providing support for the stock market and reflecting market demand for stability amid fluctuating oil prices.
- New Home Sales Growth: U.S. March new home sales rose 7.4% month-over-month to 682,000, surpassing expectations of 652,000, indicating a robust recovery in the housing market that could bolster economic confidence.
- Positive Earnings Outlook: As of Tuesday, 83% of the 354 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year, demonstrating sustained corporate profitability that may further drive stock market gains.
See More
US Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index surged by 1.20%, reaching an all-time high, driven by robust performance in technology stocks, reflecting increased investor confidence in the tech sector's growth potential.
- Intel's Strong Surge: Intel's stock rose over 13%, leading chipmakers after Apple indicated exploratory discussions with Intel and Samsung to produce key processors in the US, which is expected to enhance Intel's market share and profitability.
- Economic Data Impact: March new home sales in the US rose by 7.4% month-over-month to 682,000 units, surpassing expectations and indicating signs of recovery in the housing market, while the April ISM services index fell slightly below expectations, highlighting the complexities of economic recovery that may influence future monetary policy.
- Crude Oil Price Drop: WTI crude oil prices fell by more than 4% as calm returned to the Middle East, easing geopolitical risks, which is expected to positively impact inflation expectations and provide support for the stock market.
See More
Revvity (RVTY) Q1 2026 Earnings Transcript
See More
Revvity Reports Strong Q1 2026 Earnings with Strategic Divestiture
- Performance Growth: Revvity generated $711 million in revenue for Q1 2026, achieving a 3% year-over-year growth, with an adjusted operating margin of 23.6% exceeding expectations, indicating improved operational efficiency that is likely to enhance future profitability.
- Strategic Restructuring: The company plans to divest its immunodiagnostics business in China, which accounted for approximately 6% of total revenue last year, aiming to address persistent policy challenges, with the transaction expected to close within two years while retaining a minority stake in the new entity.
- Outlook Update: Management has revised its full-year 2026 targets, projecting organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30, reflecting confidence in operational execution and adaptability to market changes.
- Cash Flow Performance: The company reported free cash flow of $115 million in Q1, resulting in a robust 97% conversion of adjusted net income into cash flow, demonstrating strong capital management, while the net debt to adjusted EBITDA leverage ratio stood at 2.8x, indicating a healthy financial position.
See More
Reasons to Avoid Investing in Revvity
- Organic Growth Weakness: Revvity's organic revenue growth averaged only 2.9% annually over the past two years, lagging behind the sector, indicating waning demand in its core business and the need for product and market strategy improvements to remain competitive.
- Declining Adjusted Operating Margin: The company's adjusted operating margin has decreased by 6 percentage points over the last five years, currently standing at 27%, which raises concerns among shareholders about future profitability improvements to enhance investment appeal.
- Falling EPS: Revvity's earnings per share (EPS) has declined by 14.7% annually over the past five years, suggesting that while revenue may have increased, the company's fixed cost structure has hindered its ability to adapt to decreasing demand, negatively impacting profitability.
- Overpriced Market Valuation: With a forward P/E ratio of 20.3 and a stock price of $112.79, Revvity's shares appear to be priced for significant positive expectations, leading analysts to recommend that investors consider other stocks with better potential.
See More
Market Capitalization Comparison: Revvity vs Clorox
- Market Cap Comparison: Revvity Inc (Ticker: RVTY) has a market capitalization of $11.78 billion compared to Clorox Co (Ticker: CLX) at $11.53 billion, indicating Revvity's relative strength in the market, which may attract more investor interest.
- Investor Misconceptions: Many novice investors mistakenly compare company values solely based on stock prices; however, market capitalization provides a more accurate assessment of a company's value, aiding investors in making informed decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to hold the stock, particularly as large funds tend to focus on companies valued over $10 billion.
- Stock Performance: At Thursday's close, Revvity's stock rose approximately 7.6%, while Clorox fell about 0.2%, reflecting positive market sentiment and increased investor confidence in Revvity.
See More
U.S. Stocks Close Higher, Led by Tech Gains
- Tech Stock Surge: Intel's stock soared over 12% after Apple held exploratory talks with Intel and Samsung Electronics for U.S. processor production, indicating strong market confidence in tech stocks and driving gains across chipmakers.
- Oil Price Decline: WTI crude oil prices fell more than 3% as the ceasefire in the Middle East eased geopolitical risks, providing support for the stock market and reflecting market demand for stability amid fluctuating oil prices.
- New Home Sales Growth: U.S. March new home sales rose 7.4% month-over-month to 682,000, surpassing expectations of 652,000, indicating a robust recovery in the housing market that could bolster economic confidence.
- Positive Earnings Outlook: As of Tuesday, 83% of the 354 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year, demonstrating sustained corporate profitability that may further drive stock market gains.
See More
US Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index surged by 1.20%, reaching an all-time high, driven by robust performance in technology stocks, reflecting increased investor confidence in the tech sector's growth potential.
- Intel's Strong Surge: Intel's stock rose over 13%, leading chipmakers after Apple indicated exploratory discussions with Intel and Samsung to produce key processors in the US, which is expected to enhance Intel's market share and profitability.
- Economic Data Impact: March new home sales in the US rose by 7.4% month-over-month to 682,000 units, surpassing expectations and indicating signs of recovery in the housing market, while the April ISM services index fell slightly below expectations, highlighting the complexities of economic recovery that may influence future monetary policy.
- Crude Oil Price Drop: WTI crude oil prices fell by more than 4% as calm returned to the Middle East, easing geopolitical risks, which is expected to positively impact inflation expectations and provide support for the stock market.
See More
Revvity (RVTY) Q1 2026 Earnings Transcript
See More
Revvity Reports Strong Q1 2026 Earnings with Strategic Divestiture
- Performance Growth: Revvity generated $711 million in revenue for Q1 2026, achieving a 3% year-over-year growth, with an adjusted operating margin of 23.6% exceeding expectations, indicating improved operational efficiency that is likely to enhance future profitability.
- Strategic Restructuring: The company plans to divest its immunodiagnostics business in China, which accounted for approximately 6% of total revenue last year, aiming to address persistent policy challenges, with the transaction expected to close within two years while retaining a minority stake in the new entity.
- Outlook Update: Management has revised its full-year 2026 targets, projecting organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30, reflecting confidence in operational execution and adaptability to market changes.
- Cash Flow Performance: The company reported free cash flow of $115 million in Q1, resulting in a robust 97% conversion of adjusted net income into cash flow, demonstrating strong capital management, while the net debt to adjusted EBITDA leverage ratio stood at 2.8x, indicating a healthy financial position.
See More
